39
Soft Tissue Tumors Soft Tissue Tumors Sybile Val, MD Department of Surgery SUNY Downstate Medical Center SUNY Downstate Medical Center October 29 , 2009

Soft Tissue Tumors.ppt - Department of Surgery at SUNY ... · Soft Tissue Tumors Sybile Val, MD Department of Surgery SUNY Downstate Medical Center October 29, 2009

Embed Size (px)

Citation preview

Soft Tissue TumorsSoft Tissue Tumors

Sybile Val, MDDepartment of Surgery

SUNY Downstate Medical CenterSUNY Downstate Medical CenterOctober 29, 2009

Case PresentationCase Presentation

• 52 YOM presented to ED on 7/22 with52 YOM presented to ED on 7/22 with abdominal pain

Case PresentationCase Presentation

• PMH: • SocHx:PMH:– Schizophrenia

• PSH:

SocHx:– ½ PPD x 20 yrs

– Jehovah’s Witness

– None

• Meds:– Risperdal

• ALL:– NKDA

Case PresentationCase Presentation

• Vital:Vital:– 99.1 106/74 97 18 98%

• Exam• Exam:– Diffusely tender

• Labs:

103 1010

11

34284

136

4.9

103

26117

10

1.1

Hospital CourseHospital Course• HD #1 • HD#4HD #1

– GI consult

– Surgery consult

HD#4– Tachycardic 110‐120

• HD#5• HD#2

– EGD

– Transferred to surgical service

– Colonoscopy

– VIR biopsy

– Spiked to 101.5

– Cultures and CBC

17• HD#3– Started on diet

• Hct: 17

Path: Malignant small round blue cell tumor with extensive necrosis andtumor with extensive necrosis and degenerative changes

Hospital CourseHospital Course

• HD#6HD#6– Started on Epogen

• HD#10– Discharged home with surgical follow up

S i l Cli iSurgical Clinic

Pt asymptomatic

dHct increased to 30

Scheduled for resection

Hospital Course

• 8/23/09

Hospital Course

8/23/09– Pt admitted for bowel prep

• 8/24/09• 8/24/09– Exploratory laporatomy

E i f h i• Evacuation of hemoperitoneum

• Resection of small bowel mesenteric mass

• Small bowel resection x 2• Small bowel resection x 2

• Partial omentectomy

• Cholecystectomyy y

Intra-OperativelyIntra Operatively

Intra-OperativelyIntra Operatively

Intra-OperativelyIntra Operatively

Post-OperativelyPost Operatively

• POD#0 • POD#4– Hypotensive in RR– Central line placed

– Started on clears– Iron and Epogen

d– Started on pressors

• POD#1Weaned off all pressors

resumed

• POD#10– Hct 23– Weaned off all pressors

– Extubated in afternoon

• POD#3

Hct 23

• POD#11– Discharged home

– NGT removed– Hct 19

PathologyPathology

• Abdominal MassAbdominal Mass– 40x20x8cm in aggregate (19x11x5)

High grade spindle cell sarcoma– High grade spindle cell sarcoma

While Val @ VAWhile Val @ VA

• POD #49POD #49– Presented to ER with 3 days of abdominal pain associated with nausea and vomitingassociated with nausea and vomiting

– AVSS

– Exam: LLQ pain– Exam: LLQ pain

– Labs:93

1512

39402

130

5.4

93

30130.6

158

Hospital CourseHospital Course

• Admitted to surgical serviceAdmitted to surgical service– Conservative management x 2 days

Taken to the OR 8/15/09– Taken to the OR 8/15/09• Exploratory laporatomy

– carcinomatosis encountered

• Evacuation of hemoperitoneum (500ml)

• Lysis of adhesions

Hospital CourseHospital Course

• POD#6POD#6 – Extubated

• POD#7• POD#7– Started on clears

/– Made DNR/DNI by family

• Currently– Tolerating regular diet

– Awaiting hospice

Questions??

Soft Tissue Tumors

Soft Tissue SarcomaSoft Tissue Sarcoma

• Collective term for diverse group of malignanciesg p g• Arise from mesoderm• Represent 1% of all adult tumors• Represent 15% of pediatric tumors• Occur anywhere in the body

– 43%  extremities– 15%  retroperitoneum– 13% viscera13%  viscera– 10%  trunk

• More than 50 distinct histological subtypes

Soft Tissue SarcomaSoft Tissue Sarcoma

• Etiology is uncleart o ogy s u c ea• Tumor grade is the best indicator of

– Biological aggressivenessg gg– Metastatic potential– Grade is defined by:

• Tumor cellularity• Nuclear atypia• Degree of necrosisDegree of necrosis• Mitotic activity

• Present as asymptpmatic mass

• Indications for biopsy:Indications for biopsy:– Mass larger than 5cm

History of growth– History of growth

– Persists for more than 4 weeks

SURGERY is the FOUNDATION of the treatment of STS

For intra-abdominal or retroperitoneal sarcomas:

FNA or CNB  is not indicated

Except:Suspicion for lymphoma or germ cell tumor

Tissue diagnosis for preoperative therapy

Tissue dx for unresectable disease

S t d t t i f th iSuspected metastasis from another primary

• Poor prognostic factors:Poor prognostic factors:– Large size

Deep seated– Deep seated 

– Retroperitoneal vs. extremity

Hi h d– High grade

– High stage

P i i i– Positive margins

Specific Therapy by SiteSpecific Therapy by Site

• Extremity (43%)y ( )– Surgery alone

– Amputation

Limb Sparing Surgery and– Limb Sparing Surgery and adjuvant radiation

• Standard of care  • Retroperitoneal and intra‐abdominal (15%)abdominal (15%)– Surgery with negative margins

– Chemotherapy

– Radiation (??)• Adjuvant

• Preoperative

• Intra‐abdominal

• Regional LymphadenectomyRegional Lymphadenectomy– Not indicated

Only 2 6% of sarcomas metastasize to lymph– Only 2.6% of sarcomas metastasize to lymph nodes

Treatment OptionsTreatment Options

• Radiation Therapy • ChemotherapyRadiation Therapy– Recommended for high grade resected STS

Chemotherapy– Controversial

– Favorable px factors for – Improves local recurrence

No impact on survival

response to chemo:• Young Age

• Good performance status– No impact on survival

– Optimal timing unclear

• Good performance status

• Absence of liver mets

• Liposarcoma or synovial hi t lhistology

Recurrence Rates:Extremity 8 20%– Extremity 8‐20%

– Retroperitoneum 38‐50%

Could we have done somethingCould we have done something different in this case??

• Retrospective Analysis1991 2005– 1991‐2005

– Included only patients with advanced disease• Primary tumor or local recurrence not amendable to complete surgical resectionsurgical resection

• Presence of metastatic disease

• Goal:– Determine the efficacy of palliative chemotherapy

• Responders: those who achieved a complete or partial response• Non‐responders: All others

ll l d f f h l d h/l• Overall survival: measured from start of chemo until death/last follow up

– Determine whether specific factors influence the outcome of chemotherapyof chemotherapy

Median time to progression was

3 months

23% of pts were li @ 2alive @ 2 years

189/488

(39%)

299/488

(61%)

• Concluded:– Palliative chemotherapy in advanced STS should be regarded as a standard treatment option in the 

t f th i tmanagement of these aggressive tumors

– Doxorubicin based combinations regimens may be associated with superior survival to that achieved with psingle agent

– Factors predictive of superior survival included• Younger age

• Absence of bone mets

• Synovial or liposarcoma histology

Surgical resection is the most effective potentially curative therapy for soft tissue sarcomas regardless of origintissue sarcomas regardless of origin

In SummaryIn Summary

• Soft tissue sarcomas arise from mesenchymalSoft tissue sarcomas arise from mesenchymal tissues

• Extremities and retroperitoneum are most• Extremities and retroperitoneum are most common sites

MRI i f d di i i i d li• MRI is preferred diagnostic imaging modality

• Biospy may be considered for extremity lesions

• Surgical resection is mainstay of treatmentg y

Thank You…